Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have earned a consensus rating of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $23.20.

A number of brokerages have commented on STOK. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Chardan Capital reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Cantor Fitzgerald raised Stoke Therapeutics to a “strong-buy” rating in a report on Wednesday, May 14th. Finally, HC Wainwright decreased their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th.

Insider Activity

In other news, Director Edward M. Md Kaye sold 10,382 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. This represents a 6.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 6,471 shares of the company’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $10.03, for a total value of $64,904.13. Following the sale, the insider now owns 25,782 shares of the company’s stock, valued at approximately $258,593.46. This represents a 20.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 24,748 shares of company stock worth $225,687. 11.30% of the stock is currently owned by company insiders.

Institutional Trading of Stoke Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of STOK. Rhumbline Advisers lifted its position in shares of Stoke Therapeutics by 6.0% during the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock worth $545,000 after buying an additional 2,787 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Stoke Therapeutics by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock worth $1,028,000 after buying an additional 1,330 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Stoke Therapeutics by 8.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 342,129 shares of the company’s stock worth $3,774,000 after buying an additional 25,995 shares during the last quarter. Swiss National Bank lifted its position in shares of Stoke Therapeutics by 20.4% during the 4th quarter. Swiss National Bank now owns 67,300 shares of the company’s stock worth $742,000 after buying an additional 11,400 shares during the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in shares of Stoke Therapeutics during the 4th quarter worth $113,000.

Stoke Therapeutics Trading Up 0.4%

STOK stock opened at $10.94 on Thursday. The firm has a market capitalization of $597.29 million, a PE ratio of -5.21 and a beta of 1.20. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $17.58. The business’s 50 day simple moving average is $8.58 and its 200 day simple moving average is $9.67.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. As a group, sell-side analysts predict that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.